Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
Standalone net profit reached Rs 317 crore for FY26 versus Rs 12 crore loss previous year, with Q4 profit at Rs 167 crore.
Board approved enabling proposal for fundraising via equity/convertible securities through various methods subject to shareholder approval.
Exceptional items include Rs 35 crore gain from Dr. Reddy's legal settlement and Rs 10 crore charge for new labour codes impact.